The Phase III study, MOBILE, is a multicenter, randomized, double-blind, placebo-controlled trial evaluating the long-term efficacy and safety of MDR-001 in approximately 750 patients across 50 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results